noom microdose glp-1 Microdosing meets weight loss as turns a DIY trend into a medical program What if you could start
Description
The 2026 EASO pharmacotherapy update explicitly ranks tirzepatide above semaglutide for weight loss, while supporting semaglutide as the better-documented option for liver fibrosis endpoints in MASH [1]
On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
doi: 10.1016/S0944-7113(99)80014-2
In percentage terms, VAT reduction averaged 15 to 20 percent over the study period
J Diabetes Res (2016) 2016:8917578
Pour into a bowl and top with granola, coconut flakes, and sliced fruit
